Roslyn J. Francis

Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.

A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.

Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.

Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.

Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres.

Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions.

A gelatin liver phantom of suspended 90Y resin microspheres to simulate the physiologic microsphere biodistribution of a postradioembolization liver.

Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.

A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.

Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging.

A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment.

Ga-somatostatin analogue PET-CT: Analysis of costs and benefits in a public hospital setting.

In search of the vulnerable patient or the vulnerable plaque: F-sodium fluoride positron emission tomography for cardiovascular risk stratification.

Comparison between gallium-68 citrate positron emission tomography-computed tomography and gallium-67 citrate scintigraphy for infection imaging.

Coronary artery 18F-NaF PET analysis with the use of an elastic motion correction software.

Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.

Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.

Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.

F-Sodium Fluoride Positron Emission Tomography Activity Predicts the Development of New Coronary Artery Calcifications.

Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.

The Australasian Radiopharmaceutical Trials Network: Clinical Trials, Evidence, and Opportunity.

[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

UpFrontPSMA: a randomized phase 2 study of sequential Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).

The effect of Vitamin-K and Colchicine on Vascular Calcification Activity in subjects with Diabetes Mellitus (ViKCoVaC): A double-blind 2x2 factorial randomized controlled trial.

Repeatability of image features extracted from FET PET in application to post-surgical glioblastoma assessment.

The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial.

Imaging Inflammation in Patients and Animals: Focus on PET Imaging the Vulnerable Plaque.

Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group.

The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective.

Subcutaneous sarcoidosis (Darier-Roussy sarcoidosis) with extensive disease on positron emission tomography: A case report and review of the literature.

Fully automatic prognostic biomarker extraction from metastatic prostate lesion segmentations in whole-body [Ga]Ga-PSMA-11 PET/CT images.

Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art review.

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.

Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group.

Targeted alveo-pleural fistula endobronchial valve treatment using ventilation scintigraphy.

[F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial.

Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [Ga]Ga-PSMA-11 PET images.

Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.

Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): Selective effect of eicosapentaenoic acid?

Prospective inter- and intra-tracer repeatability analysis of radiomics features in [Ga]Ga-PSMA-11 and [F]F-PSMA-1007 PET scans in metastatic prostate cancer.

Quantitative [Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study.

The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy - A prospective cohort study.

Overall survival with [Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.

Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer.

Plasma lipoprotein(a) is associated with calcification activity of the thoracic aorta and aortic valve in statin naïve individuals with diabetes mellitus.

[18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program.

[Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.